Movement-test gains reported for low-oxygen drug combination in Parkinson’s-like mice

Two drugs given six weeks after symptoms were induced

Researchers induced alpha-synuclein buildup and movement difficulties in mice, then began oral treatment six weeks later with GBT601 and PT2399. The drugs are intended to recreate some effects of low-oxygen exposure by reducing oxygen released into tissues while limiting the body’s compensatory production of red blood cells.

The mice had already developed movement problems when daily oral treatment began. The report does not show improvement in every behavioral measure or establish protection of dopamine-producing neurons.

ScienceAlert reports that, over six weeks, mice given the two-drug combination improved on pole-descending and cage-hang tests. The combination also reduced excess brain oxygen and a marker of lipid damage in brain tissue.

The reported result tests a drug-based alternative to breathing low-oxygen air and began treatment only after movement problems appeared. It remains preclinical: the study did not establish benefit or safety in people, did not report dopamine-neuron counts in the main paper, and did not improve an anxiety-like behavior measure.